专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080193920A1 Methods and systems for producing recombinant viral antigens 失效
标题翻译：用于产生重组病毒抗原的方法和系统
公开(公告)号：US20080193920A1
公开(公告)日：2008-08-14
申请号：US12077046
申请日：2008-03-14
申请人： Suzanne Zebedee , Genevieve Inchauspe , Marc S. Nasoff , Alfred M. Prince
发明人： Suzanne Zebedee , Genevieve Inchauspe , Marc S. Nasoff , Alfred M. Prince
IPC分类号： C12Q1/70
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/16222 , C12Q1/703 , Y10S436/82
摘要： The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.
摘要翻译：本发明涉及表达编码重组HIV和HCV抗原的脱氧核糖核酸的重组表达载体。将这些重组表达载体转化到宿主细胞中并用于表达大量这些抗原的方法中。本发明还提供含有某些分离的抗原的组合物，含有这些抗原的诊断系统和测定体液以检测针对本发明的抗原的抗体的存在的方法。

2. 发明授权

US07326535B2 Immunoreactive peptides from Epstein-Barr virus 失效
标题翻译：来自爱泼斯坦 - 巴尔病毒的免疫反应肽
公开(公告)号：US07326535B2
公开(公告)日：2008-02-05
申请号：US10442456
申请日：2003-05-21
申请人： Richard S. Smith , Gary R. Pearson , D. Elliot Parks , Susan Pothen Varghese
发明人： Richard S. Smith , Gary R. Pearson , D. Elliot Parks , Susan Pothen Varghese
IPC分类号： G01N33/569 , G01N33/53 , G01N33/543 , G01N33/58
CPC分类号： C07K16/085 , A61K38/00 , A61K39/00 , C07K14/005 , C07K2317/734 , C12N2710/16222 , C12N2710/16622 , Y10S435/975 , Y10S436/82
摘要： Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.
摘要翻译：公开了爱泼斯坦 - 巴尔病毒（EBV）特异性多肽。还公开了这些多肽用于产生多肽特异性抗体以及EBV相关疾病的诊断和治疗的用途。

3. 发明授权

US07198892B2 Hepatitis-C virus type 4, 5 and 6 有权
标题翻译：丙型肝炎病毒4型，5型和6型
公开(公告)号：US07198892B2
公开(公告)日：2007-04-03
申请号：US11090952
申请日：2005-03-25
申请人： Peter Simmonds , Peng Lee Yap , Ian Hugo Pike
发明人： Peter Simmonds , Peng Lee Yap , Ian Hugo Pike
IPC分类号： C12Q1/00 , C12Q1/70 , G01N33/53 , C07K7/00 , C07K17/00 , A61K38/00 , A61K39/00
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/29 , C12N2770/24222 , C12N2770/24234 , C12Q1/706 , C12Q1/707 , G01N33/56983 , G01N2333/18 , G01N2469/20 , Y10S436/811 , Y10S436/82 , Y10S436/825 , Y10S530/806 , Y10S530/811 , Y10S530/826
摘要： The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
摘要翻译：本发明涉及包含至少一种含有8个或更多个连续核苷酸的多核苷酸的多核酸组合物，其对应于来自HCV 3型核心/ E1区域的位置417至957的区域的核苷酸序列; 和/或跨越HCV 3型NS3区域的位置4664至4730的区域; 和/或跨越HCV 3型NS3 / 4区的位置4892至5292的区域; 和/或跨越HCV3型BR36亚组的NS5区域的位置8023至8235的区域; 和/或从核心区域的核苷酸379开始的HCV型4a的编码区; 和/或HCV 4型的编码区; 和/或HCV 5型的编码区，其中所述核苷酸编号相对于表1所示的HCV核酸的编号，并且所述多核苷酸与已知的HCV I型具有至少一个核苷酸差异，和/ 或HCV 2型基因组，或其补体。

4. 发明授权

US07179470B2 Hepatitis-C virus testing 失效
标题翻译：丙型肝炎病毒检测
公开(公告)号：US07179470B2
公开(公告)日：2007-02-20
申请号：US10396964
申请日：2003-03-25
申请人： Peter Simmonds , Shui-Wan Chan , Peng Lee Yap
发明人： Peter Simmonds , Shui-Wan Chan , Peng Lee Yap
IPC分类号： G01N33/53 , A61K38/00
CPC分类号： C07K14/005 , A61K39/00 , C07K16/109 , C07K2319/00 , C12N2770/24222 , C12Q1/707 , G01N33/56983 , G01N2333/18 , G01N2333/186 , Y10S436/82
摘要： New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.
摘要翻译：已经鉴定并测序了新型的丙型肝炎病毒（HCV），称为HCV-3和HCV-4。已经鉴定了HCV-2，HCV-3和HCV-4多肽的抗原性区域。描述了HCV的免疫测定及其抗体，其允许对HCV的血液样品进行更全面的筛选，并且允许进行HCV基因分型。

5. 发明申请

US20070014813A1 Conserved motif of hepatitis C virus E2/NS1 region 失效
标题翻译：丙型肝炎病毒E2 / NS1区域的保守主题
公开(公告)号：US20070014813A1
公开(公告)日：2007-01-18
申请号：US11522614
申请日：2006-09-18
申请人： Amy Weiner , Michael Houghton
发明人： Amy Weiner , Michael Houghton
IPC分类号： A61K39/395 , A61K39/12
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/109 , C07K2317/34 , C12N2770/24222 , Y10S436/82 , Y10S530/806 , Y10S530/826
摘要： The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.
摘要翻译：推定的丙型肝炎病毒（HCV）糖蛋白E2 / NS1的高变区（E2HV）在约氨基酸384至约氨基酸414之间，是HCV的快速进化区域，并且可能处于阳性免疫选择。在这个高变区内新发现的基序是相对于氨基酸的特征而言是免疫原性的并且是保守的。在许多分离株中，该基序位于氨基酸401至406或407之间。该基序的发现允许另外的材料和方法来治疗和诊断HCV。

6. 发明授权

US07135185B1 Conserved motif of hepatitis C virus E2/NS1 region 失效
标题翻译：丙型肝炎病毒E2 / NS1区域的保守主题
公开(公告)号：US07135185B1
公开(公告)日：2006-11-14
申请号：US08438183
申请日：1995-05-09
申请人： Amy J. Weiner , Michael Houghton
发明人： Amy J. Weiner , Michael Houghton
IPC分类号： A61K39/29 , C07K14/18
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/109 , C07K2317/34 , C12N2770/24222 , Y10S436/82 , Y10S530/806 , Y10S530/826
摘要： Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a pharmaceutically acceptable carrier, such as a diphtheria toxoid.
摘要翻译：描述了包含免疫原性多肽和药学上可接受的载体的免疫原性组合物。免疫原性多肽包含氨基酸序列Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa- Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile（SEQ ID NO：8）。免疫原性多肽可以偶联至药学上可接受的载体，例如白喉类毒素。

7. 发明授权

US06861212B1 NANBV diagnostics and vaccines 失效
标题翻译： NANBV诊断和疫苗
公开(公告)号：US06861212B1
公开(公告)日：2005-03-01
申请号：US08441355
申请日：1995-05-15
申请人： Michael Houghton , Qui-Lim Choo , George Kuo
发明人： Michael Houghton , Qui-Lim Choo , George Kuo
IPC分类号： A61K39/00 , C07K14/18 , C07K16/10 , C12Q1/68 , C12Q1/70 , G01N33/53 , G01N33/00 , G01N33/566 , G01N33/537
CPC分类号： C12Q1/6853 , A61K39/00 , C07K14/005 , C07K16/109 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2770/24222 , C12Q1/6858 , C12Q1/701 , C12Q1/707 , Y02A50/451 , Y10S435/948 , Y10S435/96 , Y10S436/811 , Y10S436/82 , C12Q2521/107 , C12Q2521/101
摘要： A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
摘要翻译：提供了源自丙型肝炎病毒（HCV）的cDNA序列家族。这些序列编码与存在于非A非乙型肝炎（NANBH）的个体中存在的抗体进行免疫反应但是在感染甲型肝炎病毒或乙型肝炎病毒的个体中不存在的抗原，并且在对照个体中也不存在。 HCV cDNA序列与乙型肝炎病毒（HDV）和HBV的序列缺乏实质同源性。 HCV cDNA编码的氨基酸序列与黄病毒序列的比较表明，HCV可能与黄病毒有关。HCV cDNA序列及其中编码的多肽可用作检测和治疗HCV的试剂。本发明中提供的试剂也可用于分离NANBH剂，用于组织培养中这些试剂的繁殖，以及筛选用于HCV的抗病毒剂。

8. 发明申请

US20040211727A1 Method for the extra-corporeal qualitative and/or quantitative recording of neurotoxic substances in the blood plasma of an individual 有权
标题翻译：用于个体血浆中神经毒物质的额外定性和/或定量记录的方法
公开(公告)号：US20040211727A1
公开(公告)日：2004-10-28
申请号：US10476440
申请日：2004-06-07
发明人： Jan Loock , Steffen R Mizner , Dieter G Weiss , Jan Stanga , Gunter W Gross
IPC分类号： B01D061/42
CPC分类号： G01N33/5088 , Y10S436/811 , Y10S436/82 , Y10S436/825
摘要： The invention relates to a method for the extra-corporeal qualitative and/or quantitative recording of neuro-toxic substances in the blood plasma of an individual. According to said method, a system containing neurones or neuronal networks, which have been cultivated on or applied to a micro-electrode array or a neuro-chip, in addition to a device for measuring the electrical activity of at least one or several of said neurones are provided, the neurones are brought into contact with a prepared sample of plasma and the electrical activity of the neurones is measured. The aim of the invention is to develop and improve said method in such a way that it supplies reliable, reproducible results for the recording of neuro-toxic substances in the blood plasma of an individual, in particular in the case of encephalopathic conditions, such as for example hepatic failure, or of coma conditions of various origins. To achieve this, prior to measurement, the blood plasma of an individual is prepared by being subjected to a filtration method, preferably an ultra-filtration method, whereby an exclusion limit, which causes the most extensive separation possible of the plasma protein from the other dissolved substances is selected, and/or prior to measurement, the blood plasma of an individual is prepared by being subjected to an extraction of liposoluble substances, using a solvent for liposoluble substances, and the ultra-filtrate or the extract containing the liposoluble substances, or both are used in succession or are blended together for the measurement.
摘要翻译：本发明涉及一种用于个体血浆中神经毒性物质的体外定性和/或定量记录的方法。根据所述方法，除了用于测量所述微电极阵列或神经芯片中的至少一个或几个的电活动的装置之外，还包括已经培养在微电极阵列或神经芯片上的神经元或神经元网络的系统提供神经元，使神经元与制备的血浆样品接触，并测量神经元的电活性。本发明的目的是开发和改进所述方法，使得其为个体血浆中的神经毒性物质的记录提供可靠且可重现的结果，特别是在脑病条件下，例如例如肝衰竭，或各种起因的昏迷状况。为了实现这一点，在测量之前，通过进行过滤方法，优选超滤方法来制备个体的血浆，由此排除极限，其导致血浆蛋白质与其他蛋白质的最广泛分离选择溶解物质，和/或测定前，通过使用脂溶性物质的溶剂，超滤液或含有脂溶性物质的提取物，对脂溶性物质进行提取，制备个体血浆，或两者连续使用或混合在一起用于测量。

9. 发明授权

US06696242B1 Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效
标题翻译：巴基斯坦戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用
公开(公告)号：US06696242B1
公开(公告)日：2004-02-24
申请号：US08470246
申请日：1995-06-06
申请人： Sergei A. Tsarev , Suzanne U. Emerson , Robert H. Purcell
发明人： Sergei A. Tsarev , Suzanne U. Emerson , Robert H. Purcell
IPC分类号： C12Q170
CPC分类号： C12N15/1131 , A61K38/00 , A61K39/00 , C07H21/00 , C07K14/005 , C12N7/00 , C12N2310/3125 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2710/14143 , C12N2770/28122 , C12N2770/28123 , Y10S436/82 , C12N2310/3521
摘要： A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译：披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。

10. 发明申请

US20030198946A1 Hepatitis-C virus testing 失效
标题翻译：丙型肝炎病毒检测
公开(公告)号：US20030198946A1
公开(公告)日：2003-10-23
申请号：US10396964
申请日：2003-03-25
申请人： COMMON SERVICES AGENCY
发明人： Peter Simmonds , Shui-Wan Chan , Peng Lee Yap
IPC分类号： C12Q001/70 , C12M001/34 , C07K014/02 , C07K016/08
CPC分类号： C07K14/005 , A61K39/00 , C07K16/109 , C07K2319/00 , C12N2770/24222 , C12Q1/707 , G01N33/56983 , G01N2333/18 , G01N2333/186 , Y10S436/82
摘要： New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.
摘要翻译：已经鉴定并测序了新型的丙型肝炎病毒（HCV），称为HCV-3和HCV-4。已经鉴定了HCV-2，HCV-3和HCV-4多肽的抗原性区域。描述了HCV的免疫测定及其抗体，其允许对HCV的血液样品进行更全面的筛选，并且允许进行HCV基因分型。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式